News

Scaling the Everest of Pharma Synthesis: A Deep Dive into Eribulin's Journey

Views: 45     Author: Unibest Industrial     Publish Time: 2024-04-19      Origin: Site

facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
sharethis sharing button

As one steps into the realm of pharmaceutical discovery, the name Eribulin, also known as Halaven, rings a powerful note. First approved in 2010 by Eisai, this non-peptide drug, intricate in its synthesis and impressive in the magnitude of its medical impact, has been nothing short of groundbreaking. Its complexity, featuring a staggering 19 chiral centers and undergoing a lengthy 62-step commercial synthesis, has led the pharmaceutic world to confer upon it the moniker of "Mount Everest". A suitable testament to its stature, indeed. Now, as we mark the recent milestone of the US FDA's approval of its generic version, released by Gland Pharma, we take a moment to reflect on Eribulin's monumental journey. In this article, we'll traverse the revenues this 'Everest' has generated for Eisai, and bring you the latest unveils within this compelling saga of Eribulin's evolution.


Eribulin Fragments

Eribulin Synthesis


Eribulin's Global Financial Triumph: A Geographic Revenue Breakdown


Annual Revenues Generated by Eribulin


The above graph presents a comprehensive record of the revenue generated by the drug Eribulin, also known as Halaven, developed by the Japanese pharmaceutical company Eisai. The data spans across different regions globally, including Japan, Americas, EMEA (Europe, Middle East, and Africa), and Asia.


From the data, it's evident that Eribulin's revenue has generally seen steady growth over the years, indicating a strong market demand for this drug. The drug appears to have its highest revenues in the Americas and EMEA regions, suggesting a substantial market presence in these areas. Notably, the revenue has nearly consistently increased every quarter, suggesting a growing acceptance and usage of the drug.


However, data for Asia (excluding Japan) and specific revenue for the second quarter of 2011 are missing, which could potentially provide more insights into the drug's performance. It would be beneficial to investigate the reasons behind these data gaps, whether it is due to the drug not being marketed or approved in these regions during that time, or due to other factors.


Potential insights that could be drawn from this data could include exploring the factors contributing to the steady growth in revenue, such as increased marketing efforts, expanded approvals in more countries, or a growing number of patients requiring this drug. Additionally, it could be insightful to evaluate the impact of any new competing drugs entering the market on Eribulin's revenue. Further, understanding the reasons behind the significantly high revenue in the Americas and EMEA regions compared to Asia could provide strategic insights for future market expansion.



Eribulin and ADCs: Navigating the New Frontiers of Eisai's Exploration

Eisai, the pharmaceutical giant behind Eribulin, continues its relentless innovation in the realm of cancer treatment. Taking Eribulin to its next evolutionary frontier, Eisai has partnered with Bristol-Myers Squibb to develop MORAb-202, an advanced antibody-drug conjugate (ADC) which conjugates Eribulin for enhanced efficacy against low sensitivity related to cancer immunotherapy.


Over the recent years, Eribulin's approval for cancer treatments has seen a steady expansion. It is now cleared for breast cancer treatments in over 85 countries, as of FY 2022, which includes major regions such as Japan, the United States, Europe, China, and Asia. Besides, it has also been approved for the treatment of liposarcoma, a type of soft tissue sarcoma, across similar geographies, marking a notable increase from over 75 countries in FY 2020 to over 85 countries in FY 2022.


Significant progress has also been observed in the development of combination treatments incorporating Eribulin. Eisai, in collaboration with Ono Pharmaceutical Co., Ltd., has been carrying out a Phase I/II study in Japan for the combination therapy of the liposomal formulation of Halaven, Eribulin's brand name, and anti-PD-1 antibody nivolumab, throughout FY 2020 to FY 2022.


Additionally, Eisai has seen the culmination of certain development studies in the United States. The FY 2020 reports the completion of a Phase I/II study treating HER2-negative breast cancer with a combination of Eribulin and a recombinant human hyaluronidase, PEGPH20 developed by Halozyme Therapeutics. Another finished study included the Phase I/II stage trial using Eribulin in combination with pembrolizumab for triple-negative breast cancer.


However, journeying through the path of innovation isn't always plain sailing. The development of an Eribulin-based treatment for bladder cancer, which was at Phase I/II stage in the US and Europe, unfortunately, had to be discontinued as per the FY 2019 report. Nevertheless, with new avenues opening and promising developments underway, Eisai's commitment to cancer treatment excellence with Eribulin is undeniably palpable.


As we observe the impressive advancements in the realm of ADCs, particularly with the ongoing development of MORAb-202, we ardently anticipate witnessing further innovations and triumphs in this cutting-edge sector of cancer therapeutics. At Unibest, our enthusiasm for such advancements is matched by our commitment to aiding global pharmaceutical companies through our extensive development solutions. Our competence especially shines in our CDMO center, renowned for its expertise in synthesizing complex multichiral molecules vital for the next generation of pharmaceuticals. We stand poised and ready to support and accelerate the journey from concept to market, ensuring that innovative treatments can reach those in need swiftly and effectively. Our doors remain open for collaborations aimed at enhancing and saving patient lives, nurturing the shared vision of a healthier future for all.